Pulmonary Hypertension in Infants, Children, and Young Adults:
The Myocardial Architecture Changes In Persistent Pulmonary ...
Nair J, Lakshminrusimha S. Update on PPHN: mechanisms and treatment. Semin Perinatol 2014;38:78–91.
Steinhorn RH. Diagnosis and treatment of pulmonary hypertension in infancy. Early Hum Dev 2013;89:865–74.
Stayer SA, Liu Y. Pulmonary hypertension of the newborn. Best Pract Res Clin Anaesthesiol 2010;24:375–86.
St John Sutton MG, Meyer RA. Left ventricular function in persistent pulmonary hypertension of the newborn. Computer analysis of the echocardiogram. Br Heart J 1983;50:540–9.
Riemenscneider TA, Nielsen HC, Ruttenberg HD, Jaffe RB. Disturbances of the transitional circulation: spectrum of pulmonary hypertension and myocardial dysfunction. J Pediatr 1976;89:622–5.
Scollan DF, Holmes A, Winslow R, Forder J. Histological validation of myocardial microstructure obtained from diffusion tensor magnetic resonance imaging. Am J Physiol 1998;275:H2308–18.
Mekkaoui C, Huang S, Chen HH, et al. Fiber architecture in remodeled myocardium revealed with a quantitative diffusion CMR tractography framework and histological validation. J Cardiovasc Magn Reson 2012;14:70.
Nielsen E, Smerup M, Agger P, et al. Normal right ventricular three-dimensional architecture, as assessed with diffusion tensor magnetic resonance imaging, is preserved during experimentally induced right ventricular hypertrophy. Anat Rec (Hoboken) 2009;292:640–51.
Smerup M, Agger P, Nielsen EA, et al. Regional and epi- to endocardial differences in transmural angles of left ventricular cardiomyocytes measured in ex vivo pig hearts: functional implications. Anat Rec (Hoboken) 2013;296:1724–34.
Streeter DD Jr, Spotnitz HM, Patel DP, Ross J Jr, Sonnenblick EH. Fiber orientation in the canine left ventricle during diastole and systole. Circ Res 1969;24:339–47.
Ferreira PF, Kilner PJ, McGill LA, et al. In vivo cardiovascular magnetic resonance diffusion tensor imaging shows evidence of abnormal myocardial laminar orientations and mobility in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson 2014;16:87.
Belik J, Halayko AJ, Rao K, Stephens NL. Fetal ductus arteriosus ligation. Pulmonary vascular smooth muscle biochemical and mechanical changes. Circ Res 1993;72:588–96.
Mall FP. On the muscular architecture of the ventricles of the human heart. Am J Anat 1911;11:211–66.
Spotnitz HM, Spotnitz WD, Cottrell TS, Spiro D, Sonnenblick EH. Cellular basis for volume related wall thickness changes in the rat left ventricle. J Mol Cell Cardiol 1974;6:317–31.
Waldman LK, Nosan D, Villarreal F, Covell JW. Relation between transmural deformation and local myofiber direction in canine left ventricle. Circ Res 1988;63:550–62.
Hales PW, Schneider JE, Burton RA, Wright BJ, Bollensdorff C, Kohl P. Histo-anatomical structure of the living isolated rat heart in two contraction states assessed by diffusion tensor MRI. Prog Biophys Mol Biol 2012;110:319–30.
Ryan JJ, Archer SL. The right ventricle in pulmonary arterial hypertension: disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure. Circ Res 2014;115:176–88.
Naeije R, Manes A. The right ventricle in pulmonary arterial hypertension. Eur Respir Rev 2014;23:476–87.
Rain S, Handoko ML, Trip P, et al. Right ventricular diastolic impairment in patients with pulmonary arterial hypertension. Circulation 2013;128:2016–25, 1–10.
Lunkenheimer PP, Niederer P. Hierarchy and inhomogeneity in the systematic structure of the mammalian myocardium: towards a comprehensive view of cardiodynamics. Technol Health Care 2012;20:423–34.
Greenbaum RA, Ho SY, Gibson DG, Becker AE, Anderson RH. Left ventricular fibre architecture in man. Br Heart J 1981;45:248–63.
Ho SY, Nihoyannopoulos P. Anatomy, echocardiography, and normal right ventricular dimensions. Heart 2006;92(Suppl 1):i2–13.
Pettigrew JB. On the arrangement of the muscular fibres in the ventricles of the vertebrate heart, with physiological remarks. Philos Trans R Soc Lond A 1864;154:445–505.
Grimm AF, Katele KV, Lin HL. Fiber bundle direction in the mammalian heart. An extension of the "nested shells" model. Basic Res Cardiol 1976;71:381–8.
Sanchez-Quintana D, Garcia-Martinez V, Climent V, Hurle JM. Morphological changes in the normal pattern of ventricular myoarchitecture in the developing human heart. Anat Rec 1995;243:483–95.
Zhang L, Allen J, Hu L, Caruthers SD, Wickline SA, Chen J. Cardiomyocyte architectural plasticity in fetal, neonatal, and adult pig hearts delineated with diffusion tensor MRI. Am J Physiol Heart Circ Physiol 2013;304:H246–52.
Lower R. Tractatus de Corde. London, United Kingdom: Early science in Oxford, 1669.
Franco D, Meilhac SM, Christoffels VM, Kispert A, Buckingham M, Kelly RG. Left and right ventricular contributions to the formation of the interventricular septum in the mouse heart. Dev Biol 2006;294:366–75.
Sanchez-Quintana D, Anderson RH, Ho SY. Ventricular myoarchitecture in tetralogy of Fallot. Heart 1996;76:280–6.
Singh GK, Levy PT, Holland MR, Hamvas A. Novel methods for assessment of right heart structure and function in pulmonary hypertension. Clin Perinatol 2012;39:685–701.
Morin FC 3rd, Egan EA. The effect of closing the ductus arteriosus on the pulmonary circulation of the fetal sheep. J Dev Physiol 1989;11:283–7.
Lakshminrusimha S, Russell JA, Wedgwood S, et al. Superoxide dismutase improves oxygenation and reduces oxidation in neonatal pulmonary hypertension. Am J Respir Crit Care Med 2006;174:1370–7.
Jones DK. The effect of gradient sampling schemes on measures derived from diffusion tensor MRI: a Monte Carlo study. Magn Reson Med 2004;51:807–15.
Satoh H, Delbridge LM, Blatter LA, Bers DM. Surface:volume relationship in cardiac myocytes studied with confocal microscopy and membrane capacitance measurements: species-dependence and developmental effects. Biophys J 1996;70:1494–504.
Cerqueira MD, Weissman NJ, Dilsizian V, et al.; American Heart Association Writing Group on Myocardial Segmentation and Registration for Cardiac Imaging. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002;105:539–42.
Smerup M, Nielsen E, Agger P, et al. The three-dimensional arrangement of the myocytes aggregated together within the mammalian ventricular myocardium. Anat Rec (Hoboken) 2009;292:1–11.
Mori S, Crain BJ, Chacko VP, van Zijl PC. Three-dimensional tracking of axonal projections in the brain by magnetic resonance imaging. Ann Neurol 1999;45:265–9.
Wakana S, Jiang H, Nagae-Poetscher LM, van Zijl PC, Mori S. Fiber tract-based atlas of human white matter anatomy. Radiology 2004;230:77–87.
Rollins N, Reyes T, Chia J. Diffusion tensor imaging in lissencephaly. AJNR Am J Neuroradiol 2005;26:1583–6.
Caulfield JB, Borg TK. The collagen network of the heart. Lab Invest 1979;40:364–72.
Leveling The Field For Babies With Persistent Pulmonary Hypertension
If he can figure out which babies will be born unable to breathe properly, Dr. Stephen M. Black thinks he can help change that.
"When these kids are born, you have a short amount of time to intervene or you get brain damage," says Dr. Black, cell and molecular physiologist at the Medical College of Georgia Vascular Biology Center.
Unfortunately, persistent pulmonary hypertension comes as a surprise in full-term babies, says Dr. Jatinder J.S. Bhatia, chief of the MCG Section of Neonatology. The pregnancy seems uneventful until the hours following birth when breathing trouble requires rapid transport to a neonatal intensive care unit.
"What happens in utero is that all your gas exchange is through the placenta, so there is only about 8 percent of cardiac output actually going through the lungs," says Dr. Black. "When you are born, obviously there is 100 cardiac output and you need to breathe."
When babies can't breathe well, physicians quickly determine whether the primary problem is the heart or lungs, Dr. Bhatia says. When it's the lungs, babies first get oxygen therapy and possibly mechanical ventilation. If it is pulmonary hypertension, the powerful vasodilator, nitric oxide, is used to reduce high pressures in the pulmonary circuit and allow the transition to a normal circulation. Neonatologists also have begun using the popular erectile dysfunction drug, Viagra, to dilate tiny pulmonary vessels.
If these therapies fail, they turn to the more invasive extracorporeal membrane oxygenation, which resembles heart-lung bypass used during heart surgery. This approach is most helpful for newborns with conditions such as pulmonary hypertension as well as aspirating waste products in utero, congenital heart disease and congenital diaphragmatic hernia.
Dr. Black's focus is the babies whose vessels have become thick-walled, inflexible pipes that cannot transition to an elastic state. Flexibility enables adequate blood to get into the lungs so it can be replenished with oxygen then head back to the heart which pumps it out to the body.
"If you can keep the kids alive for four or five days, the blood vessels remodel back to what they should be," says Dr. Black, who joined the MCG faculty in March. He wants vessels ready for their job at birth
He's studying how factors that regulate blood vessel expansion go awry in the two to six babies per 1,000 with persistent pulmonary hypertension and finding many cards stacked again them.
"Basically the whole pathway is shot," he says. "The main vasodilator in the lungs is nitric oxide and the main vasoconstrictor is endothelin. They have to be in very good balance. What happens in our animal model – and there is evidence that it happens in kids who die from this – is that nitric oxide synthase, the enzyme that makes nitric oxide, decreases in utero and endothelin levels increase. When you lose the vasodilator and you gain proliferative response, essentially the muscle cells just get bigger. The end result is these kids can die as soon as they are born."
He and Dr. Jeffrey Fineman, a whole animal physiologist and physician at the University of California, San Francisco, are using sheep as a surgical model for this condition.
They have found one way endothelin enlarges smooth muscle cells on exterior blood vessel walls is by activating an enzyme that makes free radicals, which are reactive, unpaired electrons that work as signaling molecules.
Free radicals are fine, even necessary, as long as they are available in the proper numbers. But at least one of these radicals, hydrogen peroxide, escapes from smooth muscle cells into endothelial cells, which line blood vessels where, in a double-whammy to flexibility, it inhibits the expression and the activity of nitric oxide synthase.
"A whole host of enzymes are involved in vasodilation and a host of enzymes are involved in vasoconstriction. What happens in these children is all the vasoconstrictors go up and the vasodilators go down," says Dr. Black. "We think hydrogen peroxide is a key molecule in there."
In this unfortunate scenario, even nitric oxide malfunctions.
Nitric oxide dilates vessels by activating a protein that stimulates production of cyclic GMP. At low levels, hydrogen peroxide activates the protein that enables production of cyclic GMP, enabling a chain reaction that results in calcium being pumped out of smooth muscle cells and blood vessels relaxing. Endothelin does just the opposite.
"We have found that if you chronically give the cells hydrogen peroxide, it down regulates those enzymes. So your nitric oxide generation is decreased and the ability to activate cyclic GMP has gone away as well," says Dr. Black.
As if that weren't bad enough, levels of phosphodiesterase, an enzyme that degrades cyclic GMP, rise, Dr. Black suspects because of the increase in oxidative stress. This phosphodiesterase increase is the reason Viagra, a phosphodiesterase inhibitor, is used for these babies.
Now that they better understand the complex scenario, Dr. Black and his colleagues want to look at the plasma of mothers and babies with persistent pulmonary hypertension for biomarkers that predict a baby is headed for trouble.
They also are looking at therapies, probably antioxidant therapy delivered right to cells, to stop signals from free radicals that result in bulky, dysfunctional pulmonary blood vessels at birth. "The driving force in these babies is the free radicals that make the muscles grow," says Dr. Black.
Dr. Black's other primary research interest is perinatal stroke, in which nitric oxide synthase also appears a key player and a bad one. "Nitric oxide gets activated in stroke and kills neurons," he says. He and colleague Dr. Donna Ferriero, pediatric neurologist at the University of California, San Francisco, have developed a culture model to study what happens to the hippocampus when it's deprived of critical oxygen and glucose. They are dissecting the no-doubt, complex chain of signaling that leads to neuronal death in babies and looking for viral delivery systems that can help protect brain cells.
Dr. Black is principal investigator on four National Institutes of Health grants, an American Heart Association-Pacific Mountain Affiliates grant and a grant from Foundation Leducq, a French foundation supporting international efforts to combat cardiovascular disease. He recently was appointed to the National Heart, Lung and Blood Institute's Board of Scientific Councilors and NHLBI's Program Project Review Committee. Dr. Black came to MCG from the University of Montana and previously worked at the University of California, San Francisco, and Northwestern University.
Persistent Severe Pulmonary Hypertension Strong Predictor Of ... - Healio
August 05, 2016
2 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on . Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.Com.Back to Healio
In patients who undergo transcatheter aortic valve replacement, the persistence of severe pulmonary hypertension after the procedure may be a stronger predictor of 1-year mortality compared with severe pulmonary hypertension at baseline.
Researchers for a new study evaluated 990 consecutive patients with severe aortic stenosis who underwent TAVR with the third-generation 18F CoreValve ReValving system (Medtronic) from June 2009 to April 2013. Patients underwent transthoracic echocardiography before TAVR, within 3 days after TAVR, and at 1, 5 and 12 months. Analysis focused on three categories of pulmonary hypertension before TAVR:
The researchers evaluated clinical endpoints including cardiac death, NYHA class and rate of HF hospitalization at 1 month and 1 year after the procedure. Endpoints were determined based on the Valve Academic Research Consortium (VARC)-2 definitions.
At 1-month follow-up, there was no significant difference across the three groups in overall mortality. Compared with patients with no or moderate pulmonary hypertension, those with severe pulmonary hypertension had a significantly higher proportion of NYHA class III to IV HF (26% for severe pulmonary hypertension group vs. 12% for no pulmonary hypertension group and 10% for moderate pulmonary hypertension group) and also a higher rate of HF hospitalization (7% vs. 3% and 3%, respectively).
At 1 year, patients with moderate pulmonary hypertension (HR = 1.5; 95% CI, 1.3-3.2) and severe pulmonary hypertension (HR = 2.3; 95% CI, 1.8-2.8) showed higher rates of overall mortality and higher rates of cardiac mortality (HR = 1.3; 95% CI, 1.1-2.1 and HR = 1.7; 95% CI, 1.3-2.5, respectively). Vs. Those with no pulmonary hypertension.
After 1 month, 32% of patients with moderate pulmonary hypertension and 35% of patients with severe pulmonary hypertension had at least a 15-mm Hg reduction in sPAP. No additional reductions were seen at 1 year.
Regardless of baseline pulmonary hypertension at baseline, patients who demonstrated reductions in pulmonary hypertension 1 month after TAVR had significantly lower rates of atrial fibrillation, severe mitral regurgitation and severely depressed left ventricular ejection fraction (< 30%).
According to Cox regression analysis, the following were independent predictors of 1-year overall mortality: severe baseline pulmonary hypertension (HR = 1.6; 95% CI, 1.1-2.3), severe pulmonary hypertension 1 month after TAVR (HR = 2.4; 95% CI, 1.5-2.8) creatinine clearance less than 30 mL/min (HR = 1.9; 95% CI, 1.3-2.6) and severe mitral regurgitation (HR = 2.9; 95% CI, 2.3-3.9).
"The persistence of a severe [pulmonary hypertension] after TAVR is a stronger predictor of 1-year mortality than a baseline severe [pulmonary hypertension]," the researchers wrote. "An improved [pulmonary hypertension] is not associated with improved survival. Notably, the benefit of TAVR in terms of quality of life is substantial in patients with and without a reduction of sPAP at early follow-up." – by Jennifer Byrne
Disclosure: The researchers report no relevant financial disclosures.
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on . Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.Com.Back to Healio
Comments
Post a Comment